Publicacións nas que colabora con Iria Vázquez Urio (15)

2022

  1. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20

2016

  1. Use of human pharyngeal and palatine tonsils as a reservoir for the analysis of B-cell ontogeny in 10 paired samples

    Clinical Otolaryngology, Vol. 41, Núm. 5, pp. 606-611

2013

  1. Erratum: ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia (Oncogene (2013) 32 (803) DOI: 10.1038/onc.2012.593)

    Oncogene

2011

  1. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia

    Haematologica, Vol. 96, Núm. 10, pp. 1448-1456

2006

  1. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia

    Oncogene, Vol. 25, Núm. 13, pp. 1862-1870

  2. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia

    International Journal of Cancer, Vol. 118, Núm. 8, pp. 1945-1953

  3. Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter

    British Journal of Haematology, Vol. 134, Núm. 2, pp. 137-144

2005

  1. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib

    Cancer Genetics and Cytogenetics, Vol. 160, Núm. 1, pp. 22-26

  2. Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia [10]

    Leukemia

  3. Erratum: NUP98 is fused to HOXA9 in a variant complex t(7;11;13;17) in a patient with AML-M2 (Cancer Genetics and Cytogenetics (2005) 157 (151-6))

    Cancer Genetics and Cytogenetics

  4. NUP98 is fused to HOXA9 in a variant complex t(7;11;13;17) in a patient with AML-M2

    Cancer Genetics and Cytogenetics, Vol. 157, Núm. 2, pp. 151-156

2004

  1. Cryptic ins(2;11) with clonal evolution showing amplification of 11q23-q25 either on hsr(11) or on dmin, in a patient with AML-M2 [4]

    Leukemia

  2. Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells

    Oncogene, Vol. 23, Núm. 1, pp. 311-316

  3. Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements

    Genes Chromosomes and Cancer, Vol. 40, Núm. 3, pp. 179-189

2003

  1. NUP98 is fused to Adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, with a new translocation t(10;11)(q25;p15)

    Cancer Research, Vol. 63, Núm. 12, pp. 3079-3083